AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

AbbVie (ABBV) reported stronger-than-expected Q2 2025 results, with revenue reaching $15.42 billion, a 6.7% year-over-year increase that beat estimates by 2.35%, and EPS of $2.97, exceeding consensus by 2.77%. This performance was driven by robust growth in key products like Rinvoq, which saw US sales surge 42.8% to $1.45 billion, and Neuroscience, up 24.1% to $2.68 billion. These gains effectively mitigated the anticipated 58.1% year-over-year decline in Humira revenue to $1.18 billion due to biosimilar competition, highlighting AbbVie's successful diversification strategy.

Analysis

AbbVie's Q2 2025 results demonstrate a successful strategic pivot, with headline numbers beating analyst expectations. The company reported revenue of $15.42 billion, a 6.7% year-over-year increase, and EPS of $2.97, surpassing consensus estimates by 2.35% and 2.77% respectively. This top-line growth was achieved despite a steep, anticipated 58.1% year-over-year decline in Humira revenue, which fell to $1.18 billion and also missed analyst forecasts. The negative impact from Humira's loss of exclusivity was effectively counteracted by exceptional performance in other key franchises. Specifically, the Neuroscience division grew 24.1% to $2.68 billion, and immunology drug Rinvoq posted strong global growth, with U.S. sales climbing 42.8% and international sales up 39.5%. However, the report also highlights significant weakness in the Aesthetics portfolio, where total revenue fell 8% year-over-year to $1.28 billion, missing estimates. Key products within this segment, Botox Cosmetic and the Juvederm Collection, both saw year-over-year declines and failed to meet analyst targets. This mixed performance across the portfolio, coupled with the stock's recent -0.8% return versus the S&P 500's +2.7% gain, aligns with the Zacks Rank #3 (Hold) rating, suggesting a period of transition where new growth drivers are balancing legacy declines and sectoral weaknesses.

Key Decisions for Investors

• Investors should recognize that AbbVie's core growth narrative is successfully shifting from Humira to its Neuroscience and next-generation immunology assets like Rinvoq, whose strong performance validates the company's long-term strategy.
• It is crucial to monitor the Aesthetics franchise, as the underperformance in both Botox Cosmetic and Juvederm represents a significant headwind that is currently offsetting some of the strength seen in the pharmaceutical segments.
• Given the stock's recent underperformance and the mixed results at the product level, a neutral or 'Hold' stance is warranted until there is clearer evidence that growth in new products can consistently overcome both the Humira decline and the persistent weakness in the Aesthetics business.